纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | NOR1 |
Uniprot No | O15162 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-288aa |
氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MDKQNSQMNA SHPETNLPVG YPPQYPPTAF QGPPGYSGYP GPQVSYPPPP AGHSGPGPAG FPVPNQPVYN QPVYNQPVGA AGVPWMPAPQ PPLNCPPGLE YLSQIDQILI HQQIELLEVL TGFETNNKYE IKNSFGQRVY FAAEDTDCCT RNCCGPSRPF TLRIIDNMGQ EVITLERPLR CSSCCCPCCL QEIEIQAPPG VPIGYVIQTW HPCLPKFTIQ NEKREDVLKI SGPCVVCSCC GDVDFEIKSL DEQCVVGKIS KHWTGILREA FTDADNFGIQ FPLDLDVK |
预测分子量 | 34 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOR1重组蛋白的3篇参考文献示例(注:以下内容为模拟,实际文献请通过数据库查询确认):
1. **《NOR1重组蛋白调控鼻咽癌细胞凋亡的分子机制研究》**
作者:Li X, Chen Y, Wang H
摘要:研究通过构建NOR1重组蛋白过表达模型,证实其在鼻咽癌细胞中通过激活线粒体凋亡通路(Bax/Bcl-2/caspase-3)抑制肿瘤增殖,为靶向治疗提供依据。
2. **《NOR1重组蛋白在氧化应激中的神经保护作用》**
作者:Zhang R, Liu T, Zhou M
摘要:利用重组NOR1蛋白处理神经元细胞,发现其通过上调Nrf2/ARE通路减少ROS积累,显著缓解氧化应激损伤,提示其在神经退行性疾病中的潜在应用。
3. **《NOR1重组蛋白与血管平滑肌细胞表型转化的关系》**
作者:Wang J, Li S, Xu F
摘要:研究证明NOR1重组蛋白通过抑制mTOR信号通路,调控血管平滑肌细胞从合成型向收缩型转化,为动脉粥样硬化的治疗提供新靶点。
NOR1 (Neuron-Derived Orphan Receptor 1), encoded by the *NR4A3* gene, is a member of the NR4A subfamily of nuclear receptors. These ligand-independent transcription factors regulate diverse cellular processes, including proliferation, apoptosis, metabolism, and inflammation. NOR1 is expressed in multiple tissues, with notable roles in the nervous, immune, and vascular systems. Its activity is tightly controlled by stress signals, growth factors, and cytokines, acting through mitogen-activated protein kinase (MAPK) or cAMP signaling pathways.
NOR1 gained attention due to its involvement in cancer biology. Chromosomal translocations involving *NR4A3* (e.g., t(9;22)(q22;q12)) are hallmark genetic alterations in extraskeletal myxoid chondrosarcoma (EMC), leading to aberrant NOR1 fusion proteins (e.g., EWSR1::NOR1) that drive oncogenesis. These fusion products disrupt transcriptional regulation, promoting tumor cell survival and proliferation.
Recombinant NOR1 proteins are engineered for functional studies and therapeutic exploration. Produced via bacterial or mammalian expression systems, they retain key domains: a DNA-binding domain (DBD) for target gene interaction and a ligand-binding domain (LBD) that facilitates co-regulator recruitment. Recombinant NOR1 enables *in vitro* investigations into its transcriptional activity, post-translational modifications (e.g., phosphorylation), and interactions with signaling pathways.
Clinically, recombinant NOR1 serves as an antigen for antibody development in diagnostic assays, aiding EMC detection. It also supports drug screening to identify compounds modulating NR4A3 activity, with potential applications in cancer and inflammatory diseases. Research on NOR1 continues to uncover its dual roles as a tumor suppressor or promoter, depending on cellular context, highlighting its complexity as a therapeutic target.
×